Ardent Health Lawsuit Spurs 33% Stock Plunge While Analysts See $1.63B Revenue
Ardent Health faces a securities fraud class action over undisclosed collections problems, triggering a 33% stock price drop and inviting plaintiff applications by March 9, 2026. Analysts forecast Q1 EPS of $0.34 and revenue of $1.63 billion, while its P/E ratio is 6.45 and debt-to-equity ratio is 1.84.
1. Class Action Lawsuit
Ardent Health is facing a securities fraud class action over undisclosed collections problems covering July 18, 2024 to November 12, 2025. Plaintiffs must file lead applications by March 9, 2026, with investors pointing to a 33% decline in share value since the issues emerged.
2. Analyst Forecasts
For the quarter ending March 31, analysts expect EPS of $0.34 and revenue of $1.63 billion, reflecting modest growth in its hospital services segment. The earnings announcement is scheduled for March 4, 2026, setting a performance benchmark during ongoing litigation.
3. Financial Metrics
Ardent's P/E ratio stands at 6.45, suggesting a low valuation relative to earnings, while its debt-to-equity ratio of 1.84 indicates significant leverage. The company maintains a current ratio of 2.08 and earnings yield of 15.50%, highlighting strong liquidity and potential investor returns despite debt levels.